This week, the benefits of using telemedicine to address sleep disorders and provide cystic fibrosis care; rituximab may be an effective adjuvant treatment for systemic sclerosis and PAH; the FDA says facilities should move away from crisis capacity conservation measures; and researchers call for standardization to identify and categorize environmental exposures when assessing interstitial lung disease progression.

Read the full coverage here:

American Academy of Sleep Medicine updates guidance on telemedicine for sleep disorders

Rituximab safe, potentially effective adjuvant treatment for systemic sclerosis-PAH

Clinician survey highlights benefits of telehealth for cystic fibrosis care delivery

FDA says HCP can transition away from reusing disposable respirators

Insights on identification, remediation of environmental exposures in patients with ILD

References:

Copeland CR, et al. Chest. 2021;doi:10.1016/j.chest.2021.02.021.

FDA. FDA Recommends Transition from Use of Decontaminated Disposable Respirators - Letter to Health Care Personnel and Facilities. https://www.fda.gov/medical-devices/letters-health-care-providers/fda-recommends-transition-use-decontaminated-disposable-respirators-letter-health-care-personnel-and. Accessed April 9, 2021.

Perkins RC, et al. Ann Am Thorac Soc. 2021;doi:10.1513/AnnalsATS.202012-1484RL.

Shamim-Uzzaman QA, et al. J Clin Sleep Med. 2021;doi:10.5664/jcsm.9194.

Zamanian RT, et al. Am J Respir Crit Care Med. 2021;doi:10.1164/rccm.202009-3481OC.